The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of afatinib in patients with advanced/metastatic solid tumors harboring NRG1 gene fusions: A novel, prospective real-world outcomes study based on single-patient protocol data.
 
Stephen V. Liu
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Eisai; Elevation Oncology; Genentech; Gilead Sciences; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Lilly; MSD Oncology; Novartis; Regeneron; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - Alkermes (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Rain Therapeutics (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Lori Ann E. Minasi
Employment - Boehringer Ingelheim
Stock and Other Ownership Interests - Alexion Pharmaceuticals
 
Matthias Herpers
Employment - Boehringer Ingelheim; ClinStat
 
Claas Frohn
Employment - Boehringer Ingelheim